Francisco Leonardo Galastri

Francisco Leonardo Galastri

Auto-generated profile, based on publicly available information

Francisco Leonardo Galastri

Center of Interventional Medicine, Hospital Israelita Albert Einstein, São Paulo, (SP), Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PFPriscila Mina Falsarella
Priscila Mina Falsarella
FNFelipe Nasser
Felipe Nasser
BABreno Boueri Affonso
Breno Boueri Affonso
FGFrancisco Leonardo Galastri
Francisco Leonardo Galastri
JMJoaquim Mauricio da Motta-Leal-Filho
Joaquim Mauricio da Motta-Leal-Filho
MKMarcelo Katz
Marcelo Katz

27 January 2020 in World Journal of Hepatology
Verified
Journal Article
Open access
FGFrancisco Leonardo Galastri
Francisco Leonardo Galastri
FNFelipe Nasser
Felipe Nasser
BABreno Boueri Affonso
Breno Boueri Affonso
LVLeonardo Guedes Moreira Valle
Leonardo Guedes Moreira Valle
BOBruno Calazans Odísio
Bruno Calazans Odísio
NWNelson Wolosker
Nelson Wolosker
Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma

24 May 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
IAIon Agirrezabal
Ion Agirrezabal
LJLuiz Sérgio Pereira Grillo Junior
Luiz Sérgio Pereira Grillo Junior
FNFelipe Nasser
Felipe Nasser
VBVictoria K. Brennan
Victoria K. Brennan
DBDiogo Bugano
Diogo Bugano
JMJoaquim Mauricio Motta-Leal-Filho
Joaquim Mauricio Motta-Leal-Filho
Aims Hepatocellular carcinoma (HCC) is a severe condition with poor prognosis that places a significant burden on patients, caregivers, and healthcare systems. Selective internal radiation therapy (SIRT) is a treatment available to patients with HCC which addresses some of the limitations of alternative treatment options. A cost-effectiveness analysis was undertaken into the use of SIRT using Y-90 resin microspheres for the treatment of unresectable, intermediate- and late-stage HCC in Brazil. Materials and methods A partitioned-survival model was developed, including a tunnel state for patients downstaged to receive treatments with curative intent. Sorafenib was the selected comparator, a common systemic treatment in Brazil and for which comparative evidence exists. Clinical data were extracted from published sources of pivotal trials, and effectiveness was measured in quality-adjusted life-years (QALYs) and life-years (LYs). The analysis was conducted from the Brazilian private payer perspective and a lifetime horizon was implemented. Comprehensive sensitivity analyses were conducted. Results LYs and QALYs were higher for SIRT with Y-90 resin microspheres versus sorafenib (0.27 and 0.20 incremental LYs and QALYs, respectively) and costs were slightly higher for SIRT (R$15,864). The base case incremental cost-effectiveness ratio (ICER) was R$77,602 per QALY. The ICER was mostly influenced by parameters defining the sorafenib overall survival curve and SIRT had a 73% probability of being cost-effective at a willingness-to-pay threshold of R$135,761 per QALY (three times the per-capita gross domestic product in Brazil). Overall, sensitivity analyses confirmed the robustness of the results indicating that SIRT with Y-90 resin microspheres is cost-effective compared with sorafenib. Limitations A rapidly evolving treatment landscape in Brazil and worldwide, and the lack of local data for some variables were the main limitations. Conclusions SIRT with Y-90 resin microspheres is a cost-effective option compared with sorafenib in Brazil.

10 August 2022 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
KSKatia Pinheiro de Souza
Katia Pinheiro de Souza
GGGuilherme Moratti Gilberto
Guilherme Moratti Gilberto
GMGuilherme Cayres Mariotti
Guilherme Cayres Mariotti
PFPriscila Mina Falsarella
Priscila Mina Falsarella
FGFrancisco Leonardo Galastri
Francisco Leonardo Galastri
RGRodrigo Gobbo Garcia
Rodrigo Gobbo Garcia
Lymphoceles are collections of lymphatic fluid, mainly caused by major surgical approaches. Most lymphoceles are asymptomatic and limited, but some cases may require a medical management. Among the different techniques, transafferent nodal embolization has emerged as a minimally invasive option, with low morbidity and high resolubility, although it is not widespread in the Brazilian scenario. In this study, we report a case of lymphocele drained percutaneously, with maintenance of high output and requiring transafferent nodal embolization. Transafferent nodal embolization

19 February 2020 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
VCVithor de Oliveira Carvalho
Vithor de Oliveira Carvalho
FGFrancisco Leonardo Galastri
Francisco Leonardo Galastri
BABreno Boueri Affonso
Breno Boueri Affonso
PFPriscila Mina Falsarella
Priscila Mina Falsarella
LVLeonardo Guedes Moreira Valle
Leonardo Guedes Moreira Valle
FNFelipe Nasser
Felipe Nasser
Transarterial radioembolization (TARE) with yttrium-90 microspheres is a palliative locoregional treatment, minimally invasive for liver tumors. The neoadjuvant aim of this treatment is still controversial, however, selected cases with lesions initially considered unresectable have been enframed as candidates for curative therapy after hepatic transarterial radioembolization. We report three cases in which the hepatic transarterial radioembolization was used as neoadjuvant therapy in an effective way, allowing posterior potentially curative therapies.

22 April 2025 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
MCMarcela Juliano Silva Cunha
Marcela Juliano Silva Cunha
FGFrancisco Leonardo Galastri
Francisco Leonardo Galastri
FNFelipe Nasser
Felipe Nasser
BABreno Boueri Affonso
Breno Boueri Affonso
LVLeonardo Guedes Moreira Valle
Leonardo Guedes Moreira Valle
NWNelson Wolosker
Nelson Wolosker
Highlights ■ Higher absorbed doses are associated with positive tumor responses in patients with hepatocellular carcinoma treated with Y-90 radioembolization. ■ Personalized dosimetry may improve treatment outcomes in selected patients. ■ Dosimetric parameters such as D30, D50, and D70 also correlate positively with objective responses, emphasizing the importance of precise dose calculation in treatment planning. ABSTRACT Objective: To evaluate the relationship between the absorbed dose and radiological response in patients with hepatocellular carcinoma undergoing resin microsphere radioembolization to enhance treatment